Co‐administration of ezetimibe and simvastatin in acute myocardial infarction
Authors:
- 24 April 2007
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (5) , 357-363
Abstract
Background Recent trials in acute myocardial infarction indicate that intensive and early statin therapy that lowers low‐density lipoprotein cholesterol (LDL‐C) to ≤ 70 mg dL−1 is beneficial. The combination of statins with ezetimibe, a newly developed cholesterol‐absorption inhibitor, can lead to a further reduction in LDL‐C of up to 26%. In this study, we examined the rapidity and intensity of the lipid‐lowering effect of ezetimibe co‐administered with simvastatin immediately after myocardial infarction.Materials and methods Sixty patients admitted for acute myocardial infarction were randomized to receive either simvastatin 40 mg (SIMVA), a combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA), or no lipid‐lowering drugs (NLLD) and had their lipid levels assessed 2, 4 and 7 days later.Results At baseline, cardiovascular risk factors were similar in all three groups [mean (SD) LDL‐C of 141 (36) mg dL−1]. At days 2 , 4 and 7 there was no significant change in mean LDL‐C levels in the NLLD group (−10%, −6%, and −9%, all P > 0·09), while there were significant reductions with SIMVA (−15%, −27%, and −25%, respectively, all P < 0·001 vs. day 0) and even greater reductions with co‐administration of EZE/SIMVA (−27%, −41%, and −51%, respectively, all P < 0·001 vs. day 0). The percentages of patients achieving LDL‐C below 70 mg dL−1 at days 4 and 7 were substantially greater with EZE/SIMVA (45% and 55%, respectively) than with SIMVA (5% and 10%, respectively), while no NLLD patient reached this goal. Triglyceride levels showed a progressive increase in the NLLD group (+45% at day 7, P < 0·05 vs. day 0), no change in the SIMVA group, but a decrease in the EZE/SIMVA group (−17% at day 7, P < 0·05 vs. day 0). No significant difference in HDL‐C levels, tolerability, or clinical events was observed between the three groups.Conclusions The co‐administration of ezetimibe 10 mg with simvastatin 40 mg, by inhibiting cholesterol absorption and production, allowed more patients with acute myocardial infarction to reach LDL‐C ≤ 70 mg dL−1 as early as the fourth day of treatment. The effects of such rapid and intense reduction in LDL‐C on cardiovascular morbidity and mortality need to be evaluated in future clinical endpoint studies.Keywords
This publication has 40 references indexed in Scilit:
- Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapyEuropean Heart Journal, 2006
- An Assessment of Statin Safety by HepatologistsThe American Journal of Cardiology, 2006
- A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) TrialMayo Clinic Proceedings, 2005
- Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patientsAtherosclerosis, 2005
- Serum Lipid Levels and the Risk of Venous ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Inflammation, Immunity, and HMG-CoA Reductase InhibitorsCirculation, 2004
- Beyond the LaboratoryCirculation, 2004
- Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled TrialMayo Clinic Proceedings, 2004
- Acute psychological stress reduces plasma triglyceride clearancePsychophysiology, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998